Physician profile
Basel Moussa
NPI 1467563429
$2,111.52
in general payments reported to CMS, 2019-2025
18 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.83 · 2021: $52.80 · 2022: $575 · 2023: $208 · 2024: $794 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $433.36 | 2022-2025 | Diamondback Coronary, Mitraclip, Pressurewire |
| E.R. Squibb & Sons, L.L.C. | $388.19 | 2022-2025 | Camzyos |
| Medtronic, INC. | $258.36 | 2021-2025 | Onyx Frontier |
| Janssen Pharmaceuticals, INC | $156.65 | 2019-2022 | |
| Scpharmaceuticals INC. | $148.15 | 2024 | |
| Merck Sharp & Dohme LLC | $130.76 | 2022-2024 | Verquvo |
| Philips North America LLC | $114.96 | 2019-2025 | Coronary Other, (Bq9) Coronary Ivus |
| Bayer Healthcare Pharmaceuticals INC. | $100.95 | 2022 | |
| Amgen INC. | $96.83 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $68.31 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.08 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $34.89 | 2024 | Wegovy |
| Smith+Nephew, INC. | $34.69 | 2025 | Renasys Go V2 Home |
| Pfizer INC. | $33.15 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $21.18 | 2024 | Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $20.01 | 2022 | |
| Atricure, INC. | $18.67 | 2022 | |
| Cardiva Medical, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Moussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.